318 related articles for article (PubMed ID: 35123502)
1. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.
Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z
J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
3. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
5. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
6. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
7. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
8. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
9. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
11. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
12. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
13. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
14. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF
Zhang P; Guan L; Sun W; Zhang Y; Du Y; Yuan S; Cao X; Yu Z; Jia Q; Zheng X; Meng Z; Li X; Zhao L
Clin Transl Med; 2024 May; 14(5):e1694. PubMed ID: 38797942
[TBL] [Abstract][Full Text] [Related]
15. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract][Full Text] [Related]
16. Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAF
Xie F; Yan L; Li YM; Lan Y; Xiao J; Zhang MB; Jin Z; Zhang Y; Tian XQ; Zhu YQ; Li ZP; Luo YK
J Ultrasound Med; 2022 Nov; 41(11):2789-2802. PubMed ID: 35229905
[TBL] [Abstract][Full Text] [Related]
17. Papillary thyroid cancer organoids harboring BRAF
Chen D; Su X; Zhu L; Jia H; Han B; Chen H; Liang Q; Hu C; Yang H; Liu L; Li P; Wei W; Zhao Y
J Transl Med; 2023 Jan; 21(1):9. PubMed ID: 36624452
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Gao Y; Xiang D; Li W; Zheng X; Wang L; Li Z; Chen T
Front Endocrinol (Lausanne); 2022; 13():843334. PubMed ID: 35651980
[No Abstract] [Full Text] [Related]
19. An Animal Model Further Uncovers the Role of Mutant Braf
Koelsch B; Theurer S; Staniszewska M; Heupel J; Koch A; Mergener S; Walk F; Fischer C; Kutritz A; Schmid KW; Kindler-Röhrborn A
Am J Pathol; 2020 Mar; 190(3):702-710. PubMed ID: 31953036
[TBL] [Abstract][Full Text] [Related]
20. The BRAF
Ma CX; Ma XN; Liu JJ; Guan CH; Li YD; Zhao N; Mauricio D; Fu SB
Mol Cell Endocrinol; 2024 Feb; 581():112113. PubMed ID: 37989409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
